These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28153611)
61. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. Fujiwara T; Zhou J; Ye S; Zhao H Cell Death Dis; 2016 Jul; 7(7):e2300. PubMed ID: 27441652 [TBL] [Abstract][Full Text] [Related]
62. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT. Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828 [TBL] [Abstract][Full Text] [Related]
63. The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Miyamoto T Mod Rheumatol; 2006; 16(6):341-2. PubMed ID: 17164993 [TBL] [Abstract][Full Text] [Related]
64. Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1. Ohgi K; Kajiya H; Goto-T K; Okamoto F; Yoshinaga Y; Okabe K; Sakagami R Lipids Health Dis; 2018 Jun; 17(1):132. PubMed ID: 29859535 [TBL] [Abstract][Full Text] [Related]
65. L-caldesmon alters cell spreading and adhesion force in RANKL-induced osteoclasts. Chan CL; Chen JY; Shih MC; Wang CA; Liou YM J Biomed Sci; 2019 Jan; 26(1):12. PubMed ID: 30678675 [TBL] [Abstract][Full Text] [Related]
66. RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. Ishii M; Iwai K; Koike M; Ohshima S; Kudo-Tanaka E; Ishii T; Mima T; Katada Y; Miyatake K; Uchiyama Y; Saeki Y J Bone Miner Res; 2006 Jun; 21(6):965-76. PubMed ID: 16753027 [TBL] [Abstract][Full Text] [Related]
67. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
68. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321 [TBL] [Abstract][Full Text] [Related]
69. Structures and biological activity of phosphorylated dihydroceramides of Porphyromonas gingivalis. Nichols FC; Riep B; Mun J; Morton MD; Bojarski MT; Dewhirst FE; Smith MB J Lipid Res; 2004 Dec; 45(12):2317-30. PubMed ID: 15466368 [TBL] [Abstract][Full Text] [Related]
70. Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells. Kats A; Norgård M; Wondimu Z; Koro C; Concha Quezada H; Andersson G; Yucel-Lindberg T J Cell Mol Med; 2016 Jun; 20(6):1128-38. PubMed ID: 26987561 [TBL] [Abstract][Full Text] [Related]
71. Continuous application of compressive force induces fusion of osteoclast-like RAW264.7 cells via upregulation of RANK and downregulation of LGR4. Matsuike R; Tanaka H; Nakai K; Kanda M; Nagasaki M; Murakami F; Shibata C; Mayahara K; Nakajima A; Tanabe N; Kawato T; Maeno M; Shimizu N Life Sci; 2018 May; 201():30-36. PubMed ID: 29572179 [TBL] [Abstract][Full Text] [Related]
73. A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. Pokhrel NK; Kim YG; Kim HJ; Kim HJ; Lee JH; Choi SY; Kwon TG; Lee HJ; Kim JY; Lee Y J Periodontol; 2019 May; 90(5):546-554. PubMed ID: 30387495 [TBL] [Abstract][Full Text] [Related]
74. STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis. Lee J; Seong S; Kim JH; Kim K; Kim I; Jeong BC; Nam KI; Kim KK; Hennighausen L; Kim N Sci Rep; 2016 Aug; 6():30977. PubMed ID: 27485735 [TBL] [Abstract][Full Text] [Related]
75. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Li L; Sapkota M; Kim SW; Soh Y Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730 [TBL] [Abstract][Full Text] [Related]
76. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling. Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799 [TBL] [Abstract][Full Text] [Related]
77. Immune response: the key to bone resorption in periodontal disease. Taubman MA; Valverde P; Han X; Kawai T J Periodontol; 2005 Nov; 76(11 Suppl):2033-41. PubMed ID: 16277573 [TBL] [Abstract][Full Text] [Related]
78. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
79. Pin1 regulates osteoclast fusion through suppression of the master regulator of cell fusion DC-STAMP. Islam R; Bae HS; Yoon WJ; Woo KM; Baek JH; Kim HH; Uchida T; Ryoo HM J Cell Physiol; 2014 Dec; 229(12):2166-74. PubMed ID: 24891219 [TBL] [Abstract][Full Text] [Related]
80. Receptor activator of NF-κB ligand-dependent expression of caveolin-1 in osteoclast precursors, and high dependency of osteoclastogenesis on exogenous lipoprotein. Hada N; Okayasu M; Ito J; Nakayachi M; Hayashida C; Kaneda T; Uchida N; Muramatsu T; Koike C; Masuhara M; Sato T; Hakeda Y Bone; 2012 Jan; 50(1):226-36. PubMed ID: 22075210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]